Response rates ( HAMD-1750 % reduction ) at endpoint were 45 % , 31 % , and 26 % for SAMe , escitalopram , and placebo , respectively ; while remission rates ( HAM-D7 ) were 34 % for SAMe ( p = 0.003 ) , 23 % for escitalopram ( p = 0.023 ) , and 6 % for placebo .